Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor: University of California, San Diego
Listed as NCT03993353, this PHASE2 trial focuses on Cancer and Cancer of Esophagus and remains completed. Sponsored by University of California, San Diego, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2024 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
▶ Show 7 earlier versions
-
Sep 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of California, San Diego
For direct contact, visit the study record on ClinicalTrials.gov .